We are live on ! Find out more
ALLO icon

Allogene Therapeutics
ALLO

79 hedge funds and large institutions have $1.67B invested in Allogene Therapeutics in 2018 Q4 according to their latest regulatory filings, with 79 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

5,600% more call options, than puts

Call options by funds: $912K | Put options by funds: $16K

51.6% more ownership

Funds ownership: 0% → 51.6% (+52%)

Holders
79
Holders Change
+79
Holders Change %
–
% of All Funds
1.76%
Holding in Top 10
4
Holding in Top 10 Change
+4
Holding in Top 10 Change %
% of All Funds
0.09%
New
79
Increased
–
Reduced
–
Closed
–
Calls
$912K
Puts
$16K
Net Calls
+$896K
Net Calls Change
+$896K

Top Buyers

Rank Fund Capital Flow
1
TGHSA
TPG Group Holdings (SBS) Advisors
Texas
+$615M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$130M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$66.7M
4
Capital Research Global Investors
Capital Research Global Investors
California
+$66.6M
5
Capital World Investors
Capital World Investors
California
+$57.7M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Northern Trust
26
Northern Trust
Illinois
$7.71M +$7.6M +286,240 New
TCIM
27
TIAA CREF Investment Management
New York
$7.26M +$7.16M +269,424 New
CBA
28
Coastal Bridge Advisors
Connecticut
$4.87M +$4.81M +181,000 New
Federated Hermes
29
Federated Hermes
Pennsylvania
$4.71M +$4.65M +175,000 New
OAM
30
Oxford Asset Management
United Kingdom
$4.12M +$4.06M +152,871 New
SC
31
Samlyn Capital
New York
$4.04M +$3.99M +150,000 New
Macquarie Group
32
Macquarie Group
Australia
$3.95M +$3.9M +146,779 New
Charles Schwab
33
Charles Schwab
California
$3.88M +$3.83M +144,127 New
Adage Capital Partners
34
Adage Capital Partners
Massachusetts
$3.53M +$3.48M +131,000 New
SFM
35
Sphera Funds Management
Israel
$3.06M +$3.01M +113,437 New
First Trust Advisors
36
First Trust Advisors
Illinois
$2.73M +$2.7M +101,441 New
UBS AM
37
UBS AM
Illinois
$2.58M +$2.55M +95,822 New
LCM
38
Landscape Capital Management
New Jersey
$2.37M +$2.34M +87,966 New
Principal Financial Group
39
Principal Financial Group
Iowa
$1.73M +$1.71M +64,300 New
Goldman Sachs
40
Goldman Sachs
New York
$1.65M +$1.63M +61,287 New
VIA
41
Vident Investment Advisory
Georgia
$1.63M +$1.61M +60,682 New
WMSA
42
Weiss Multi-Strategy Advisers
New York
$1.35M +$1.33M +50,000 New
JMPWA
43
JP Morgan Private Wealth Advisors
California
$1.19M +$1.17M +44,000 New
SAM
44
Shikiar Asset Management
New York
$1.06M +$1.04M +39,200 New
California State Teachers Retirement System (CalSTRS)
45
California State Teachers Retirement System (CalSTRS)
California
$1.04M +$1.03M +38,715 New
Deutsche Bank
46
Deutsche Bank
Germany
$1M +$991K +37,300 New
Morgan Stanley
47
Morgan Stanley
New York
$990K +$976K +36,731 New
Bank of New York Mellon
48
Bank of New York Mellon
New York
$941K +$929K +34,968 New
Wells Fargo
49
Wells Fargo
California
$939K +$927K +34,877 New
RhumbLine Advisers
50
RhumbLine Advisers
Massachusetts
$829K +$818K +30,788 New
1
2
3 4

ALLO Hedge Fund Activity: Q4 2018 in Review

79 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Allogene Therapeutics (ALLO) for Q4 2018, worth a combined $1.67B.

Buyers outnumbered sellers: 79 funds opened new ALLO positions and 0 closed out — a net gain of 79 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was TPG Group Holdings (SBS) Advisors, opening a new position worth an estimated $615M.

  • 79 institutional investors held Allogene Therapeutics (ALLO) as of Q4 2018, up from 0 in Q3 2018.
  • Funds reported $1.67B of Allogene Therapeutics stock for Q4 2018.
  • 79 funds opened new Allogene Therapeutics positions in Q4 2018 and 0 closed out, a net change of +79 holders.
  • The largest Allogene Therapeutics buyer in Q4 2018 was TPG Group Holdings (SBS) Advisors, an estimated $615M added.

Based on aggregated 13F filings for Q4 2018.